Powering Novel Drug Discovery

Through Integrated Artificial Intelligence

Hinge Therapeutics is an early-stage biopharmaceutical company focused on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs.

The Hinge Discovery Platform, our proprietary technology, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA.

 

Current areas of interest include:

  • Hemophilia
  • Solid tumors (tumor microenvironment)
  • Hypertension (ACE inhibitor alternative)
  • CNS (including Alzheimer’s).

We are seeking investors/partners who can help us advance these programs while further establishing our “Hinge Discovery Platform” which can be applied to many other challenging targets.

We are seeking investors/partners who can help us advance these programs while further establishing our “Hinge Discovery Platform” which can be applied to many other challenging targets.